An interventional study of Best Practice and Educational Intervention in Breast Neoplasm, Colorectal Neoplasm and Female Reproductive System Neoplasm, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center — 29 open to participants now, 71 under way, 3 of them phase 3. Breast Neoplasms · M.D. Anderson Cancer Center.
Among the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center, this one is the 35th largest by planned enrollment of the 177 interventional ones that give a count, is one of 14 that started in 2017, is one of 61 with no phase, reaches primary completion later than 24 of the 70 other live ones, and was the 152nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →29 of the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 69 · Phase 3 15 · Phase 4 1
First in 1995; this study’s year is marked. 14 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 40 across the 177 interventional studies, 60 across the 53 observational. Of the 134 that completed or were terminated, 50 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
31 of the studies in Breast Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02276443M.D. Anderson Cancer CenterMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | 2026-11-30 |
| NCT05675579M.D. Anderson Cancer CenterA Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | 2026-12-31 |
| NCT00877500M.D. Anderson Cancer CenterIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | 2026-12-31 |
| NCT02754752M.D. Anderson Cancer CenterElectroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment | 2026-12-31 |
| NCT02455791M.D. Anderson Cancer CenterFeasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery | 2026-12-31 |
Add all 31 to your calendar (.ics) → With an account.
Among the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial studies how well a decision aid website works in helping to make decisions about fertility in participants with cancer. Decision aid websites that provide information about fertility preservation (maintaining your ability to have children of your own after cancer treatment) may help participants with cancer make fertility-preservation decisions.
PRIMARY OBJECTIVES:
I. To assess the effect of the Pathways to Fertility patient decision aid website (DA website) with women of reproductive age seen at the MD Anderson Oncofertility Service, in terms of improving patients' decisional conflict. (Part 1) II. To assess the effect of a multicomponent oncofertility decision support intervention (multicomponent DS intervention) compared to usual care with women of reproductive age at selected MD Anderson Houston Area Locations (HALs) on patients' decisional conflict. (Part 2)
SECONDARY OBJECTIVES:
I. To assess patients' decision-making process (e.g., preparation for decision making, decision self-efficacy, satisfaction) and decision quality (e.g., fertility preservation knowledge, clarity of patients' values, and congruence of preferences with the decision and/or treatment received). (Part 1) II. To assess patients' decision-making process (e.g., preparation for decision making, decision self-efficacy, satisfaction) and decision quality (e.g., fertility preservation knowledge, clarity of patients' values, and congruence of preferences with the decision about whether to accept fertility preservation referral and/or fertility preservation treatment). (Part 2)
EXPLORATORY OBJECTIVES:
I. To explore the acceptability of the DA website (e.g., length, clarity, ease of use) and feasibility of the research methods (e.g., preferences for viewing at home versus at the clinic, timing of viewing, website usage, recommendations for improvement), in preparation for future planned dissemination and implementation studies. (Part 1) II. To explore the feasibility of the multicomponent DS intervention and research methods (e.g., clinician's perspectives of the educational session and referral process, website usage, rates of referrals, recommendations for improving the intervention and referral process) as delivered in the HALs oncology clinics, in preparation for future planned dissemination and implementation studies. (Part 2)
OUTLINE:
PART 1: Participants review decision aid website and complete questionnaires to help researchers learn the website's effect.
PART 2: Participants are randomized into 1 of 2 arms.
ARM I: Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
ARM II: Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
Inclusion Criteria:
Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
Other: Best Practice · Other: Educational Intervention · Other: Questionnaire Administration
Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
Other: Best Practice · Other: Educational Intervention · Other: Internet-Based Intervention · Other: Questionnaire Administration
Receive standard of care
Also known as: standard of care, standard therapy
Receive educational materials
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Use decision-making website
Ancillary studies
Patients' decisional conflict (Part 1)
Will assess the effect of the Pathways to Fertility patient decision aid website (DA website) with women of reproductive age seen at the MD Anderson Oncofertility Service, in terms of improving patients' decisional conflict.
Time frame: Up to 2 months
Patients' decisional conflict (Part 2)
Will assess the effect of a multicomponent oncofertility decision support intervention (multicomponent DS intervention) compared to usual care with women of reproductive age at selected MD Anderson Houston Area Locations (HALs) on patients' decisional conflict.
Time frame: Up to 2 months
Patients' decision-making process (Part 1)
Will assess patients' decision-making process (e.g., preparation for decision making, decision self-efficacy, satisfaction) and decision quality (e.g., fertility preservation knowledge, clarity of patients' values, and congruence of preferences with the decision and/or treatment received).
Time frame: Up to 2 months
Patients' decision-making process (Part 2)
Will assess patients' decision-making process (e.g., preparation for decision making, decision self-efficacy, satisfaction) and decision quality (e.g., fertility preservation knowledge, clarity of patients' values, and congruence of preferences with the decision about whether to accept fertility preservation referral and/or fertility preservation treatment).
Time frame: Up to 2 months
Acceptability of the decision aid website (Part 1)
Will explore the acceptability of the DA website (e.g., length, clarity, ease of use) and feasibility of the research methods (e.g., preferences for viewing at home versus at the clinic, timing of viewing, website usage, recommendations for improvement), in preparation for future planned dissemination and implementation studies.
Time frame: Up to 2 months
Feasibility of the multicomponent DS intervention and research methods (Part 2)
Will explore the feasibility of the multicomponent DS intervention and research methods (e.g., clinician's perspectives of the educational session and referral process, website usage, rates of referrals, recommendations for improving the intervention and referral process) as delivered in the HALs oncology clinics, in preparation for future planned dissemination and implementation studies.
Time frame: Up to 2 months
Started Apr 2017 (actual). Primary completion is estimated for Apr 2027, 120 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 120 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.